TrialGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Yung-Jue Bang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.